Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Last trade$25.85
Day change-$1.51 (-5.52%)
Day range$25.56 – $28.09
Volume836,165
Market cap$2.05B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.05B
Price / earnings
—
Price / book
6.81×
Price / sales
7.63×
EV / sales
6.71×
EV / EBITDA
-14.14×
Profitability
Earnings per share
-$0.79
Return on assets
-9.68%
Return on equity
-19.63%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.75×
Quick ratio
2.75×
Cash ratio
1.49×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$116.77M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SDGR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$64.49M
$58.89M
$58.59M
$87.24M
$54.32M
$54.76M
$59.55M
$88.32M
Cost of revenue
$26.24M
$26.46M
$29.04M
$29.94M
$26.29M
$28.6M
$28.43M
$24.19M
Gross profit
$38.25M
$32.43M
$29.55M
$57.29M
$28.04M
$26.16M
$31.12M
$64.13M
Selling, general and administrative
$30.29M
$32.98M
$34.52M
$33.05M
$31.23M
$35.92M
$36.17M
$35.48M
Research and development
$34.09M
$41M
$43.82M
$41.4M
$42.76M
$43.14M
$45.84M
$49.36M
Total operating expenses
$64.38M
$73.98M
$78.34M
$74.45M
$73.99M
$79.06M
$82.01M
$84.84M
Operating income
-$26.13M
-$41.55M
-$48.79M
-$17.16M
-$45.95M
-$52.9M
-$50.89M
-$20.71M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$37.56M
$7.35M
-$59.62M
$32.97M
-$32.63M
-$42.89M
-$59.78M
-$39.25M
Income taxes
$156K
$1.37M
$408K
$462K
$162K
$287K
$28K
$963K
Net income
-$37.71M
$5.98M
-$60.03M
$32.51M
-$32.8M
-$43.17M
-$59.81M
-$40.22M
Net income attributable to common shareholders
-$37.71M
$5.98M
-$60.03M
$32.51M
-$32.8M
-$43.17M
-$59.81M
-$40.22M
EBITDA
-$24.67M
-$40.06M
-$47.32M
-$15.72M
-$44.48M
-$51.37M
-$49.3M
-$18.95M
Basic earnings per share
-$0.50
$0.08
-$0.81
$0.44
-$0.45
-$0.59
-$0.82
-$0.55
Diluted earnings per share
-$0.50
$0.08
-$0.81
$0.44
-$0.45
-$0.59
-$0.82
-$0.55
Recent news
Company coverage with links to the original publishers.
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.
Schrodinger (SDGR) beat earnings expectations with a loss of $0.5 per share versus consensus estimate of $0.66, representing a 24.24% earnings surprise. The company also exceeded revenue estimates at $64.49 million, up from $54.32 million year-over-year. Despite outperforming the market by 52% year-to-date, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Health Catalyst (HCAT), a peer in the Medical Info Systems industry, is expected to report results on November 5.
SOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.
Schrodinger shares surged 7.6% to close at $32.6, driven by investor optimism following the announcement of Tectora, a new biotech company co-founded by Schrodinger, NEA, and RA Capital Management focused on immunology and inflammation therapies. The company secured $55 million in Series A funding. Despite expected quarterly losses of $0.66 per share and a 15.3% revenue decline, consensus EPS estimates have been revised 72.2% higher over the past 30 days, suggesting potential for continued strength. SDGR carries a Zacks Rank #3 (Hold).
A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.